DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase

Brandt, T; Breitenstein, S; von der Hardt, H; Tümmler, B
August 1995
Thorax;Aug1995, Vol. 50 Issue 8, p880
Academic Journal
No abstract available.


Related Articles

  • Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis. Sanders, N. N.; Franckx, H.; de Boeck, K.; Hausfraete, J.; de Smedt, S. C.; Demeester, J. // Thorax;Nov2006, Vol. 61 Issue 11, p962 

    Background: In the management of cystic fibrosis (CF), rhDNase-I inhalation is widely used to facilitate the removal of the highly viscous and elastic mucus (often called sputum) from the lungs. However, an important group of CF patients does not benefit from rhDNase-l treatment. A study was...

  • Effect of Recombinant Human DNase on a1-Proteinase Inhibitor Function: An Experimental Approach to the Combined Clinical Use of rhDNase and a1-PI in CF Patients. Hansen, G.; Hoffjan, S.; Mosler, K.; Schuster, A. // Lung;2001, Vol. 179 Issue 3, p185 

    Chronic inflammation in cystic fibrosis (CF) airways leads to high concentrations of deoxyribonucleic acid (DNA) and neutrophil elastase (NE). Both play a major role in CF lung pathophysiology and are aims of new therapeutic approaches: rhDNase degrades highly viscosic DNA and a1-proteinase...

  • N-acetylcysteine Enhances Cystic Fibrosis Sputum Penetration and Airway Gene Transfer by Highly Compacted DNA Nanoparticles. Suk, Jung Soo; Boylan, Nicholas J; Trehan, Kanika; Tang, Benjamin C; Schneider, Craig S; Lin, Jung-Ming G; Boyle, Michael P; Zeitlin, Pamela L; Lai, Samuel K; Cooper, Mark J; Hanes, Justin // Molecular Therapy;Nov2011, Vol. 19 Issue 11, p1981 

    For effective airway gene therapy of cystic fibrosis (CF), inhaled gene carriers must first penetrate the hyperviscoelastic sputum covering the epithelium. Whether clinically studied gene carriers can penetrate CF sputum remains unknown. Here, we measured the diffusion of a clinically tested...

  • Pulmonary.  // Africa Health;Jul2011, Vol. 33 Issue 5, p59 

    The article reports on a 5-year follow-up for acute respiratory distress syndrome (ARDS), the large part played by nebulised recombinant human DNase in adults with cystic fibrosis, and the use of inhaled long-acting bronchodilators for patients with severe chronic obstructive pulmonary disease.

  • Endotracheal DNase for atelectasis in ventilated neonates. MacKinnon, R; Wheeler, K I; Sokol, J // Journal of Perinatology;Dec2011, Vol. 31 Issue 12, p799 

    Management of atelectasis and lung collapse in ventilated neonates remains a common challenge in the neonatal intensive care unit. Recombinant human DNase (rhDNase) is an established treatment of atelectasis in cystic fibrosis and its use is also reported in the management of asthma, respiratory...

  • Mucolytic therapy in cystic fibrosis. Wallis, Colin // Journal of the Royal Society of Medicine (Supplement);Jul2001, Vol. 94 Issue 40, p17 

    The article discusses the role of mucolytics in cystic fibrosis (CF). It presents terminologies and investigative techniques used in the study of sputum rheology when assessing the results of trials on mucolytic agent. It offers information on several products available that can assist in the...

  • Aerosol Delivery of Recombinant Human DNase I: In Vitro Comparison of a Vibrating-Mesh Nebulizer With a Jet Nebulizer. Johnson, Jeremy C.; Waldrep, J. Clifford; Guo, Jennifer; Dhand, Rajiv // Respiratory Care;Dec2008, Vol. 53 Issue 12, p1703 

    BACKGROUND: Inhaled recombinant human DNase I (rhDNuse) improves clearance of viscoelastic secretions in patients with cystic fibrosis. Because of their portability, newer-generation vibrating-mesh nebulizers offer greater convenience for the patient, but their efficiency in delivering rhDNase...

  • Inhalable Antibiotic Delivery Using a Dry Powder Co-delivering Recombinant Deoxyribonuclease and Ciprofloxacin for Treatment of Cystic Fibrosis. Michael Tsifansky; Chia-Jung Wu; Hae In Yang; Gudrun Schmidt // Pharmaceutical Research;Jan2010, Vol. 27 Issue 1, p151 

    Abstract Purpose  To achieve efficient antibiotic delivery to the cystic fibrosis (CF) airway using a single inhalable powder co-encapsulating a mucolytic and an antibiotic. Methods  Inhalable dry powders containing deoxyribonuclease and/or ciprofloxacin (DNase, Cipro, and...

  • Cystic fibrosis and survival in patients with advanced lung disease. Dasenbrook, Elliott C. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/12/2011, Vol. 342 Issue 7797, p558 

    The author reflects on a study on adult patients with cystic fibrosis and advanced lung disease, by George and colleagues, published within the issue. The study found that mortality among patients with cystic fibrosis and advanced lung disease who were treated at the Royal Brompton Hospital in...

  • Cystic Fibrosis.  // Current Medical Literature: Respiratory Medicine;2007, Vol. 21 Issue 2, p50 

    The article presents abstracts of research on cystic fibrosis. They include "Spirometry in Early Childhood in Cystic Fibrosis Patients," "Alpha1-Antitrypsin Inhalation Reduces Airway Inflammation in Cystic Fibrosis Patients" and "Human Metapneumovirus and Respiratory Syncytial Virus Infections...


Read the Article


Sign out of this library

Other Topics